MetaCap

Organogenesis (ORGO) vs PDS Biotechnology (PDSB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PDS Biotechnology (PDSB) has outperformed Organogenesis (ORGO) over the past year, gaining 3.0% versus a loss of 86.2%. Over five years, ORGO leads with a -92.2% price change compared with -92.5% for PDSB. Organogenesis is the larger company by market cap ($100.2 million vs $95.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ORGO-86.20%PDSB+2.97%
+122%+13%-96%
Nov 21, 20251 yearNov 20, 2026
ORGO-92.22%PDSB-92.26%
+38%-33%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ORGO versus PDSB key metrics
MetricORGOPDSB
Share price$0.7716$0.7774
Market cap$100.16M$95.39M
1-day change-2.23%-3.70%
YTD return-85.10%+0.96%
1-year return-86.20%+2.97%
5-year return-92.25%-92.46%
EPS (TTM)$-1.20$-0.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$564.17M—
Revenue growth (YoY)+17.04%—
Net income (latest FY)$37.03M$-34.50M
Operating margin7.92%—
Net margin6.56%—
52-week high$5.91$1.79
52-week low$0.73$0.195
Distance from 52-week high-86.93%-56.57%
Analyst consensusholdstrong_buy
Avg. price target upside—+478.85%
Average volume850.26K25.64M
Shares outstanding129.80M122.70M
Employees85421
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PDSB has outperformed ORGO by 89.2 percentage points over the past year.

About Organogenesis

ORGO stock →

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.

Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees

About PDS Biotechnology

PDSB stock →

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

ORGO vs PDSB FAQ

Which is bigger, Organogenesis or PDS Biotechnology?

Organogenesis (ORGO) is larger, with a market capitalization of $100.16M compared with $95.39M for PDS Biotechnology (PDSB).

Which stock has performed better over the past year, ORGO or PDSB?

PDSB returned +2.97% over the past 12 months, compared with -86.20% for ORGO (price return, excluding dividends). Past performance does not predict future results.

Are Organogenesis and PDS Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons